Onco-Summaries: Daily Oncology Updates at a Glance

20/02/2026

---

• The combination of venetoclax and acalabrutinib has been approved by the US FDA for CLL

---

The combination of venetoclax and acalabrutinib has been approved by the US FDA for CLL (Ref)

The US FDA has approved a sNDA for Abbvie & Genentech's venetoclax (BCL-2 inhibitor) + AstraZeneca's acalabrutinib (BTK inhibitor) for the treatment of previously untreated adult patients with CLL

• The approval is supported by data from the Phase 3 AMPLIFY trial

• Dr. Brian Koffman, co-founder and chief medical officer emeritus, CLL Society: "With the FDA approval of the combination of venetoclax and acalabrutinib for use as a front-line therapy in CLL, patients in the USA now have an all oral, time-limited option that can be important for many in choosing their treatment. CLL Society is pleased to see the number of choices available for patients growing."

Return to Top